Table 1.
Baseline Clinical Characteristics of TEAR Patients Participating in the Bio-repository Study Analysis by Treatment Group.
| All Subjects N=550 |
MTX Monotherapy N=67 |
MTX + ETA N=198 |
Triple Therapy N=103 |
“Step-up” MTX + ETA N=124 |
“Step up” Triple Therapy N=58 |
p-value | |
|---|---|---|---|---|---|---|---|
| Age (years) | 49.8 ± 12.6 | 47.3 ± 12.0 | 50.8±13.4 | 49.3 ± 12.5 | 49.9± 12.5 | 50.0 ± 11.3 | 0.40 |
| BMI | 30.0± 7.4 | 29.3± 5.6 | 29.6±7.2 | 30.3 ± 8.5 | 30.7± 7.0 | 30.0 ± 8.4 | 0.68 |
| Female | 402(72.8%) | 45(67.2%) | 146(73.7%) | 78(75.7%) | 91(73.4%) | 41(70.7%) | 0.78 |
| RF positive | 490(88.8%) | 60(89.6%) | 172(86.9%) | 95(92.2%) | 112(90.3%) | 49(84.5%) | 0.50 |
| Smoking (baseline) | 177(32.1%) | 23(34.3%) | 68(34.3%) | 29(28.2%) | 38(30.7%) | 19(32.8%) | 0.83 |
| Disease Duration (mos) | 3.6± 6.6 | 3.7 ± 6.9 | 3.5±6.5 | 4.3 ± 7.6 | 3.1± 5.3 | 4.3 ± 7.2 | 0.64 |
| DAS28 (baseline) | 5.8 ± 1.1 | 5.5 ± 1.0 | 5.8±1.0 | 5.7 ± 1.0 | 5.9± 1.1 | 5.8 ± 1.1 | 0.10 |
| CRP (baseline) (mg/l) | 13.9 ± 22.2 | 9.2 ± 11.8 | 16.2±25.6 | 13.2 ± 22.1 | 13.4± 21.3 | 14.4 ± 21.3 | 0.28 |
| ESR (baseline) (mm/h) | 31.9±24.1 | 26.5±18.4 | 32.8 ±25.3 | 31.2±23.7 | 33.8±25.4 | 31.2±22.8 | 0.33 |
| TC (baseline)(mg/dL) | 190.7 ± 47.7 | 188.7 ± 43.8 | 192.1 ± 48.4 | 187.9 ± 46.3 | 189.1 ± 49.1 | 197.9 ± 49.4 | 0.72 |
| HDL-C (baseline) (mg/dL) | 55.6 ± 15.8 | 54.8 ± 13.4 | 56.1 ± 15.7 | 57.8 ± 18.1 | 54.3 ± 14.5 | 56.7 ± 16.9 | 0.52 |
| LDL-C (baseline) (mg/dL) | 105.6 ± 36.5 | 104.3 ± 35.0 | 107.9 ± 36.3 | 98.8 ± 33.7 | 106.0 ± 38.8 | 111.6 ± 38.2 | 0.20 |
| TC/HDL (baseline) (mg/dL) | 3.5 ± 0.9 | 3.6 ± 0.8 | 3.4 ± 0.8 | 3.6 ± 0.9 | 3.6± 0.9 | 3.6 ± 0.9 | 0.26 |
| Race/Ethnicity | 0.25 | ||||||
| African American | 52(9.4%) | 5(7.5%) | 21(10.6%) | 7(6.8%) | 15(12.1%) | 4(6.9%) | |
| Caucasian | 446(80.8%) | 58(86.5%) | 154(77.8%) | 84(81.6%) | 96(77.4%) | 53(91.4%) | |
| Other | 54(9.8%) | 4(6.0%) | 23(11.6%) | 12(11.6%) | 13(10.5%) | 1(1.7%) | |
| Medications | |||||||
| Prednisone Use | 230(41.7%) | 32(47.8%) | 82(41.4%) | 47(45.6%) | 49(39.5%) | 19(32.8%) | 0.43 |
| Statin Use | 78(14.1%) | 8(11.9%) | 32(16.2%) | 14(13.6%) | 15(12.1%) | 7(12.1%) | 0.81 |
| Comorbidities | |||||||
| Diabetes | 53(9.6%) | 4(6.0%) | 19(9.6%) | 10(9.7%) | 13(10.5%) | 6(10.3%) | 0.88 |
| CV Events | 26(4.7%) | 2(3.0%) | 14(7.1%) | 4(3.9%) | 4(3.2%) | 2(3.5%) | 0.43 |
Data shown as mean ± SD, or N (%); p-values are obtained from one-way ANOVA (for continuous variables) or Chi-Square test (for categorical variables). BMI= body mass index, RF= rheumatoid factor, DAS28 = disease activity score using a 28 joint count, CRP = C reactive protein, TC= total cholesterol, HDL-C = high density lipoprotein cholesterol, LDL-C = low density lipoprotein cholesterol. Means and standard deviations for log-transformed variables are presented for the following HDL function variables: HII, PON1 activity, HDL-Hp, HDL-ApoAI and MPO.